Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

s that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. There can be no guarantee that a registrational submission will be made to the FDA based on the data described in this press release or if such registrational submission is made, that it would receive FDA approval. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol- Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Media and Investor Contacts: Rebecca Gregory, CorporateCommunications of ImClone Systems Incorporated, +1-646-638-5058,; Media: Madeline Malia, +1-609-252-3347,, or Tony Plohoros, +1-609-252-7938,, both of Bristol-Myers Squibb; Bristol-Myers Squibb;or Investors: John Elicker of Bristol-Myers Squibb, +1-212-546-3775, media@imclone.com Madeline.Malia@bms.com tony.plohoros@bms.com John.Elicker@bms.com

Web site: http://www.ERBITUX.com/

Ticker Symbol: (NASDAQ-NMS:IMCL),(NYSE:BMY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/31/2015)... CORAL SPRINGS, Fla. , March 31, 2015 ... technology (HIT) strategy and management consulting firm, has ... reference publication to enable health IT vendors, payers ... environment for the electronic prior authorization (ePA) of ... prescription prior authorization (PA) requests are completed through ...
(Date:3/31/2015)... Mar. 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... report to their offering. The global intraoperative ... of 3.5% from 2014 to 2019 It ... a number of forces that favor this market. The ...
(Date:3/31/2015)... 31, 2015 Accelerated orthodontic treatment will ... of Orthodontics 2015 Annual Session, May 15-19, as ... lectures on AcceleDent ® . Manufactured by OrthoAccel ... orthodontics, AcceleDent is a FDA-cleared, Class II medical ... much as 50 percent with just 20 minutes ...
Breaking Medicine Technology:Point-of-Care Partners Launches the ePA State Navigator 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3
... Medical ® today announced that it received Australian Therapeutic ... System for endoscopic lung volume reduction for the treatment ... lung volume reduction system for the treatment of severe ... leaving implants or foreign materials in the lung. ...
... Nev., Dec. 21, 2011   Denali Concrete Management Inc. ... patient enrollment for a phase 3 clinical study of ... in patients with moderate-to-severe Dry Eye Syndrome. This multi-center ... and Israel. The randomized, double-masked clinical trial will include ...
Cached Medicine Technology:Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 2Uptake Medical Announces TGA Approval of InterVapor for Patients With Severe Emphysema 3Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study 2
(Date:3/31/2015)... (PRWEB) March 31, 2015 At Summit Breast ... all patients in a calm and caring manner. , Summit ... diagnosis and surgical treatment of breast cancer. They treat ... but from all over the world. Their doctors continue ... publications. , The seeds for Summit Breast Care were planted ...
(Date:3/31/2015)... March 31, 2015 Dr. Uzma Parvez is ... 19th, Dr. Parvez conducted Grand Grounds Presentations at St. Michael’s ... and Managing Side Effects”. The event was attended by ... She received very positive feedback from the Grand Rounds. ... that they’ve had in a while. , Ahead, Dr. ...
(Date:3/31/2015)... Beckman Coulter is sponsoring a new ... Particulate Matter in Therapeutic Protein Injections”,” an educational session that ... counting particles in liquids, with a focus on the challenges ... to attend and will be broadcast live April 8, 2015 ... test for protein-based materials, known as USP 787 , ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Former 49ers linebacker ... than during his first year of a promising NFL career. ... Sports on Earth Senior Writer Will Leitch explores the ... league. Leitch talks about the decision making process that Borland ... preservation of health over a large paycheck, and what impact, ...
(Date:3/31/2015)... 2015 BESLER Consulting today announced ... Value of an Independent Cost Report Review.” , ... critical role in the determination of Medicare reimbursement ... understanding and review, this report can assist management ... , This white paper discusses:, ...
Breaking Medicine News(10 mins):Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 3
... UK (September 1, 2010) Faith based schools are ... standards. But are religious values at odds with legislation ... Education Management Administration and Leadership published by SAGE shows ... state diverge, with unfortunate consequences for gay students and ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... fruits and vegetables and low in saturated fats can ... mildly elevated blood pressure, Johns Hopkins University researchers say. ... (Dietary Approaches to Stop Hypertension) -- was designed to lower ...
... is the leading cause of cancer deaths worldwide, and ... successful. Furthermore, the incidence of one type of lung ... better understanding of the changes in tumor cell biology ... of an abnormal mass of tissue) that have been ...
... fewer than eight hours of sleep per night have greater ... depressive and anxious symptoms, according to a study in the ... Using an average self-reported nightly sleep duration of eight to ... association between sleep durations of less than eight hours and ...
... expedite the communication of urgent findings and improve patient ... of the Journal of the American College of ... in the United States is moving toward 24/7 coverage, ... as computed tomography (CT) and magnetic resonance imaging (MRI) ...
... A new study underscores the importance for women with a family ... testing for the BRCA1 and BRCA2 genes that make them more ... Medicine oncologist. The study, which will be published in ... Association ( JAMA ), shows women with the gene live longer ...
Cached Medicine News:Health News:Keeping faith -- schools must balance ethos with equality 2Health News:'DASH Diet' Shown to Lower Heart Attack Risk Almost 20% 2Health News:'DASH Diet' Shown to Lower Heart Attack Risk Almost 20% 3Health News:Tumor budding identified as predictor for unfavorable outcome in lung cancer 2Health News:Study links shorter sleep durations with greater risks of mental distress in young adults 2Health News:Study links shorter sleep durations with greater risks of mental distress in young adults 3Health News:Staggered radiologist work shifts improve patient care, study suggests 2Health News:Preventive cancer surgeries save women's lives 2
The full access underbody blanket is positioned on the procedure table before the patient arrives to the room....
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The ThermoWrap™ enables true normothermia (36.5°C - 37.5°C), induced hypothermia and precise rewarming....
Medicine Products: